1st Circuit Panel Upholds Dismissal Of Sarepta Securities Class Action

Mealey's (April 5, 2018, 2:04 PM EDT) -- BOSTON — Shareholders have not shown that pharmaceutical company Sarepta Therapeutics Inc. and three of its senior executives materially misrepresented investors that a 2014 new drug application (NDA) with the U.S....
To view the full article, register now.